Tags : Principia

Weekly Snapshot

PharmaShots Weekly Snapshot (Sept 07 -11, 2020)

1. Janssen’s Tremfya (guselkumab) Receives the US FDA’s Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis Published: Sept 10, 2020 | Tags:  Janssen, Tremfya, Guselkumab, Biologic, US FDA, Selective, IL-23 inhibitor, Active Psoriatic Arthritis, Severe Plaque Psoriasis, human mAb 2. Janssen Reports sBLA Submission to the US FDA for Darzalex Faspro (daratumumab […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Aug 17 -21 2020)

1. BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia Published: Aug 20, 2020 | Tags:  BioMarin, Reports, NDA, Submission, US, FDA, Vosoritide, Children, Achondroplasia 2. Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China Published: Aug 20, 2020 | Tags:  Junshi, Impact, Establish, Joint Venture, […]Read More

Pharma

Principia Biopharma files for Initial Public Offering in the US

Shots: Principia files IPO with $86mn having ticker PRNB Principia’s lead product PRN1008 (BTKi) with Ph III & II for pemphigus and immune thrombocytopenic purpura respectively In 2017, Principia collaborated with AbbVie for oral immunoproteasome inhibitors and with Sanofi for development of PRN2246 (BTKi Click here to read full press release/ article | Ref: Principia Biopharma | Image:  […]Read More